If we're resorting to a capital raise at these prices (after super positive phase 2 results)—diluting existing holders into oblivion—then let’s be real: the big pharma interest was never truly there. If it was, that path would have been a far superior option for everyone involved. And if there was real interest, why would we need to raise so much and dilute so heavily? That’s the disappointment, if you cant read between the lines to see that, then....
ATH Price at posting:
1.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)